HIV Flashcards
capsid inhibitor
lencapavir
gp120 inhibitors
fostemsavir
temsavir
CCR5 antagonist
maraviroc
NRTIs
lamivudine
emtricitabine
abacavir
tenofovir DF
tenofovir AF
zidovudine
NNRTIs
doravirine
efavirenz
rilpivirine
INSTIs
bictegravir
cabotegravir
dolutegravir
elvitegravir
raltegravir
protease inhibitors
atazanavir
darunavir
ritonavir
which drug requires tropism test
maraviroc
can use if CCR5-tropic disease
NOT if dual/mixed-tropic or CXCR4-tropic virus
which drug requires HLA-B*5701 testing
abacavir
which tenofovir causes renal, bone toxicity
DF
which regimen has an optional 4-week oral lead in period
injectable CAB+ RPV
laboratory testing parameters for HIV
HIV RNA: goal undetectable
CD4 count: goal >200 cells/mm3
when to initiate prophylaxis against opportunistic infections
CD4 count < 200 cells/mm3
when to initiate prophylaxis against PCP
CD4<200
when to initiate prophylaxis against toxoplasma
CD4<100
when to initiate prophylaxis against MAC
CD4<50 and not currently on ART
vaccinations in PLWH
live attenuated influenza contraindicated
live replicating Mpox contraindicated
MMR and varicella contraindicated if CD4<200
notable adverse effects of the integrase inhibitors
weight gain
notable drug interactions for the integrase inhibitors
all: avoid or space out divalent cations (2h before or 6h after)
bictegravir: avoid rifampin
dolutegravir: max metformin dose is 500 bid
elvitegravir: no lovastatin or simvastatin. caution with steroids and contraceptives
rilpivirine drug interactions
no PPIs
no dexamethasone
protease inhibitor drug interactions
no lovastatin or simvastatin, max doses for other statins
caution with antiarrhythmics, contraceptives
avoid PPIs with atazanavir
caution with steroids: beclomethasone preferred
PrEP options
TDF/FTC
TAF/FTC
LA CAB
which PrEP treatment can cisgender women not get
TAF/FTC
when opportunistic infection treatment is needed, when to start ART
within 2 weeks for PCP/toxo
immediately if MAC
how often is lencapavir given after first SC dose
every 6 months
which integrase inhibitor is approved as an intramuscular long-acting formulation
cabotegravir
for a treatment-naive PLWH to be prescribed abacavir, the HLA-B*5701 test must result as ____
negative
which NNRTI requires an acidic environment for absorption
rilpivirine
which integrase inhibitor is associated with a 0.1-0.4 mg/dL SCr increase due to inhibition of tubular secretion of creatinine
dolutegravir
what is the first-line initial therapy for a patient receiving long-acting cabotegravir for PrEP
DRV/c/FTC/TAF
darunavir/cobicistat/emtricitabine/tenofovir alafenamide
which protease inhibitor requires an acidic environment for absorption
atazanavir
when is 2 drug therapy dolutegravir/lamivudine not indicated
HBV co-infection
HIV RNA>500,000 copies
